D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
MRSN holding history
Mersana Therapeutics, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
MRSN overviewAll 13F holders of MRSNFull Q2 2026 holdings
- Shares (Q1 2025)
- 0
- Sold out in Q1 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 16
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q1 2025 | 0 | $0 | 0.0% | −544,463−100.0% | Sold out | Holders |
| Q4 2024 | 544,463 | $778.6K | <0.1% | −477,992−46.7% | Reduced | Holders |
| Q3 2024 | 1,022,455 | $1.93M | <0.1% | −443,125−30.2% | Reduced | Holders |
| Q2 2024 | 1,465,580 | $2.95M | <0.1% | +242,957+19.9% | Added | Holders |
| Q1 2024 | 1,222,623 | $5.48M | <0.1% | +555,240+83.2% | Added | Holders |
| Q4 2023 | 667,383 | $1.55M | <0.1% | +599,601+884.6% | Added | Holders |
| Q3 2023 | 67,782 | $86.1K | <0.1% | −917,957−93.1% | Reduced | Holders |
| Q2 2023 | 985,739 | $3.24M | <0.1% | −820,360−45.4% | Reduced | Holders |
| Q1 2023 | 1,806,099 | $7.42M | <0.1% | −529,840−22.7% | Reduced | Holders |
| Q4 2022 | 2,335,939 | $13.7M | <0.1% | −288,284−11.0% | Reduced | Holders |
| Q3 2022 | 2,624,223 | $17.7M | <0.1% | +646,293+32.7% | Added | Holders |
| Q2 2022 | 1,977,930 | $9.14M | <0.1% | −112,936−5.4% | Reduced | Holders |
| Q1 2022 | 2,090,866 | $8.34M | <0.1% | +1,445,963+224.2% | Added | Holders |
| Q4 2021 | 644,903 | $4.01M | <0.1% | +596,298+1,226.8% | Added | Holders |
| Q3 2021 | 48,605 | $458.0K | <0.1% | +8,520+21.3% | Added | Holders |
| Q2 2021 | 40,085 | $544.0K | <0.1% | −113,986−74.0% | Reduced | Holders |
| Q1 2021 | 154,071 | $2.49M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.